ResMed Inc.

ResMed Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, ResMed Inc. has 144.24M shares outstanding.

As of June 30, 2026, ResMed Inc. maintains a current ratio of 3.10, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, ResMed Inc. posted a return on equity (ROE) of 24.27, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 20.67 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.77, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 21.41, useful for judging operating efficiency across full business cycles. The company generates approximately 423,166.17 in revenue per employee across its workforce of 10,792.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times ResMed Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ResMed Inc. recorded 320.00M in income tax expense. That works out to an effective tax rate of 20.64, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.55B, leaving 1.23B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 16, 2026, ResMed Inc.'s stock has declined approximately 11.39% over the past 52 weeks.

Over the twelve months ended June 30, 2026, ResMed Inc. generated 4.57B in revenue and converted that into 1.23B in net income, yielding earnings per share of 8.43. EBITDA reached 1.72B, while operating income came in at 1.54B.

As of June 30, 2026, ResMed Inc. holds 1.19B in cash and equivalents against 667.20M in total debt, resulting in a net debt position of -654.24M. Total book value stands at 5.32B, with working capital of 2.37B providing operational flexibility.

ResMed Inc. produced 1.46B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -143.13M in capital expenditures, free cash flow totaled 1.32B - equivalent to 9.04 per share.

Over the twelve months ended June 30, 2026, ResMed Inc. posted a gross margin of 61.06, reflecting its pricing power and cost economics. The operating margin of 33.76 and net profit margin of 26.94 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, ResMed Inc. paid dividends of 1.94 per share. The dividend payout ratio of 22.95 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

ResMed Inc.'s most recent stock split took place on August 31, 2010 with a 1:2 split ratio.